Information on this site is intended for UK Healthcare
Are you a UK Healthcare Professional?
If you are a consumer and interested in finding out about
Buscopan please visit www.buscopan.co.uk
Irritable Bowel Syndrome is a common condition affecting the bowel. IBS affects up to 1 in 5 people and tends to be more common in women.
For patients suffering with the symptoms of IBS, the burden can be high. Research shows that IBS is associated with anxiety and depression and can also result in a reduced health-related quality of life for those suffering. As well as the personal impact of suffering from IBS, there is also an economic impact with research showing that IBS symptoms reduce work productivity, and increase healthcare use and costs.
Abdominal pain is one of the most common symptoms of IBS and the one that many patients find hardest to cope with. Pain is one of the main reasons why patients seek medical care.
Buscopan is a well-established medicine for the treatment of IBS symptoms associated with spasms. It is an antispasmodic that addresses the muscle spasms which cause the pain by acting upon the muscarinic receptors in the smooth muscle of the GI tract.
Buscopan does not cross the blood/brain barrier.
Buscopan starts to work within 15 minutes of oral administration, with symptom relief evident within 45 minutes.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Sanofi drug safety department on 0800 0902314.